KBC Group NV Acquires 3,285 Shares of AbbVie Inc. $ABBV

KBC Group NV lifted its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 0.5% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 672,932 shares of the company’s stock after purchasing an additional 3,285 shares during the period. KBC Group NV’s holdings in AbbVie were worth $169,336,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Souders Financial Advisors lifted its position in AbbVie by 3.4% during the 2nd quarter. Souders Financial Advisors now owns 8,246 shares of the company’s stock worth $2,075,000 after buying an additional 268 shares in the last quarter. Weinberger Asset Management Inc acquired a new stake in AbbVie in the 2nd quarter valued at about $215,000. LiftPoint Family Wealth Advisors LLC increased its position in AbbVie by 11.6% in the 2nd quarter. LiftPoint Family Wealth Advisors LLC now owns 2,129 shares of the company’s stock valued at $536,000 after acquiring an additional 221 shares in the last quarter. North Dakota State Investment Board raised its stake in shares of AbbVie by 1.7% in the second quarter. North Dakota State Investment Board now owns 52,197 shares of the company’s stock worth $13,135,000 after acquiring an additional 863 shares during the last quarter. Finally, Aviso Wealth Management lifted its position in shares of AbbVie by 5.2% during the second quarter. Aviso Wealth Management now owns 20,394 shares of the company’s stock worth $5,132,000 after purchasing an additional 1,016 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Price Performance

ABBV opened at $264.61 on Tuesday. The firm has a 50 day simple moving average of $249.34 and a 200 day simple moving average of $227.78. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $267.47. The company has a market cap of $467.52 billion, a price-to-earnings ratio of 74.75, a price-to-earnings-growth ratio of 0.88 and a beta of 0.30.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, analysts expect that AbbVie Inc. will post 14.06 EPS for the current year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were given a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 2.6%. The ex-dividend date was Wednesday, July 15th. AbbVie’s dividend payout ratio (DPR) is currently 195.48%.

Insider Activity at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.06% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several analysts have recently commented on ABBV shares. Guggenheim increased their price target on shares of AbbVie from $261.00 to $288.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. Weiss Ratings raised AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, August 4th. Barclays increased their price objective on AbbVie from $275.00 to $300.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Bank of America lifted their target price on AbbVie from $234.00 to $276.00 and gave the company a “buy” rating in a research note on Friday, July 10th. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a research note on Tuesday, June 23rd. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and a consensus target price of $275.95.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.